Siemens Healthineers

Nothing really meaningful, …

04/08/22 -"… but this could last into the next business year. We have moderately reduced our profitability expectations for the current and coming business years as we believe the mix of supply shortages and ..."

PDF page sample
Pages
72
Language
English
Published on
04/08/22
Download
You may also be interested by these reports :
13/11/26
DiaSorin’s Q3 performance exceeded expectations, with revenue acceleration supported by all segments and improved profitability. Full-year guidance ...
13/11/26
Coloplast reported weak Q4 FY26 numbers: revenue beat consensus slightly (+1.1%), but adjusted EBIT missed sharply (-8.4%). More importantly, the new ...
12/11/26
Sonova’s H1 results exceeded expectations. The Hearing Instruments segment drove sales growth, partly offset by weakness in Cochlear Implants. ...
12/11/26
Ottobock delivered a solid 3Q26, in line on sales and slightly ahead on profitability. Core revenues grew by +9.0% to €433.4m (organic +6.4%). B2B ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO